American Heart Journal
Volume 148, Issue 3 , Pages 422-429 , September 2004

A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: Lack of effect

  • John G. Webb, MD

      Affiliations

    • Divisions of Cardiology and Nephrology and the Pharmacy Department, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    • Corresponding Author InformationReprint requests: John G. Webb, MD, Director of Cardiac Catheterization, St. Paul's Hospital, Room 5202A, 1081 Burrard St, Vancouver, British Columbia, Canada V6Z 1Y6.
    • ,
  • Gordon E. Pate, MB, MSc

      Affiliations

    • Divisions of Cardiology and Nephrology and the Pharmacy Department, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Karin H. Humphries, MBA, DSc

      Affiliations

    • Divisions of Cardiology and Nephrology and the Pharmacy Department, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Christopher E. Buller, MD

      Affiliations

    • Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Stephen Shalansky, PharmD

      Affiliations

    • Divisions of Cardiology and Nephrology and the Pharmacy Department, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Ali Al Shamari, MD

      Affiliations

    • Divisions of Cardiology and Nephrology and the Pharmacy Department, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Anton Sutander, MD

      Affiliations

    • Divisions of Cardiology and Nephrology and the Pharmacy Department, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Tracey Williams

      Affiliations

    • Divisions of Cardiology and Nephrology and the Pharmacy Department, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Rebecca S. Fox, MSc

      Affiliations

    • Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Adeera Levin, MD

      Affiliations

    • Divisions of Cardiology and Nephrology and the Pharmacy Department, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada

Received 7 November 2003 ,Accepted 30 March 2004.

References 

  1. Baliga R, Ueda N, Walker PD, et al.  Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis. 1997;29:465–477
  2. Katholi RE, Woods WT, Taylor GJ, et al.  Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998;32:64–71
  3. Gruberg L, Mintz GS, Mehran R, et al.  The prognostic implications of further renal function deterioration within 48 hours of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542–1548
  4. Baker CS. Prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv. 2003;58:532–538
  5. Andrews NP, Prasad A, Quyyumi AA. N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol. 2001;37:117–123
  6. Tepel M, van der Giet M, Schwarzfeld C, et al.  Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180–184
  7. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40:1383–1388
  8. Tadros GM, Mouhayar EN, Akinwande AO, et al.  Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. J Invasive Cardiol. 2003;15:311–314
  9. Allaqaband S, Tumuluri R, Malik AM, et al.  Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv. 2002;57:279–283
  10. Vallero A, Cesano G, Pozzato M, et al.  Contrast nephropathy in cardiac procedures (no advantages with prophylactic use of N-acetylcysteine (NAC)]). G Ital Nefrol. 2002;19:529–533
  11. Durham JD, Caputo C, Dokko J, et al.  A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62:2202–2207
  12. Boccalandro F, Amhad M, Smalling RW, et al.  Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv. 2003;58:336–341
  13. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol. 2002;89:356–358
  14. Briguori C, Manganelli F, Scarpato P, et al.  Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002;40:298–303
  15. Kay J, Chow WH, Chan TM, et al.  Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention (a randomized controlled trial). JAMA. 2003;289:553–558
  16. Baker CS, Wragg A, Kumar S, et al.  A rapid protocol for the prevention of contrast-induced renal dysfunction (the RAPPID study). J Am Coll Cardiol. 2003;41:2114–2118
  17. Levey AS, Bosch JP, Lewis JB, et al.  A more accurate method to estimate glomerular filtration rate from serum creatinine (a new prediction equation: Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130:461–470
  18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  19. Sadeghi HM, Stone GW, Grines CL, et al.  Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003;108:2769–2775
  20. Best PJ, Lennon R, Ting HH, et al.  The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39:1113–1119
  21. Safirstein R, Andrade L, Vieira JM. Acetylcysteine and nephrotoxic effects of radiographic contrast agents (a new use for an old drug). N Engl J Med. 2000;343:210–212
  22. Birck R, Krzossok S, Markowetz F, et al.  Acetylcysteine for prevention of contrast nephropathy (meta-analysis). Lancet. 2003;362:598–603
  23. Isenbarger DW, Kent SM, O'Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol. 2003;92:1454–1458
  24. McCullough PA. Beyond serum creatinine (defining the patient with renal insufficiency and why?). Rev Cardiovasc Med. 2003;4(Suppl 1):S2–6
  25. Hoffmann U, Fischereder M, Kruger B, et al.  The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15:407–410
  26. Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet. 1991;20:123–134
  27. Borgstrom L, Kagedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol. 1986;31:217–222
  28. Hetzel GR, May P, Hollenbeck M, et al.  Assessment of radiocontrast media induced renal vasoconstriction by color coded duplex sonography. Ren Fail. 2001;23:77–83
  29. Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdoses. Cochrane Database Syst Rev 2002:CD003328
  30. De Caro L, Ghizzi A, Costa R, et al.  Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers. Arzneimittelforschung. 1989;39:382–386
  31. Scaduto RC, Gattone VH, Martin LF, et al.  Elevation of renal glutathione enhances ischemic injury. Ren Physiol Biochem. 1991;14:259–270
  32. Heyman SN, Goldfarb M, Shina A, et al.  N-acetylcysteine ameliorates renal microcirculation (studies in rats). Kidney Int. 2003;63:634–641
  33. Aspelin P, Aubry P, Fransson SG, et al.  Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491–499
  34. Stevens MA, McCullough PA, Tobin KJ, et al.  A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy (results of the PRINCE Study: Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation). J Am Coll Cardiol. 1999;33:403–411
  35. Dean LS. Protection from contrast-induced nephropathy (is the answer in?). Catheter Cardiovasc Interv. 2003;58:342–343
  36. Gare M, Haviv YS, Ben-Yehuda A, et al.  The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol. 1999;34:1682–1688
  37. Mueller C, Buerkle G, Buettner HJ, et al.  Prevention of contrast media-associated nephropathy (randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty). Arch Intern Med. 2002;162:329–336
  38. Harmoinen A, Lehtimaki T, Korpela M, et al.  Diagnostic accuracies of plasma creatinine, cystatin C, and glomerular filtration rate calculated by the Cockcroft-Gault and Levey (MDRD) formulas. Clin Chem. 2003;49:1223–1225
  39. Coresh J, Astor BC, McQuillan G, et al.  Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis. 2002;39:920–929

☆ Supported in part by Tyco Canada Inc, Shiley Canada Inc, Vancouver Hospital Interventional Trust, and the St Paul's Hospital Foundation.

PII: S0002-8703(04)00187-5

doi: 10.1016/j.ahj.2004.03.041

American Heart Journal
Volume 148, Issue 3 , Pages 422-429 , September 2004

Article Tools

* Image Usage & Resolution